Shares of Portage Biotech Inc. (NASDAQ:PRTG – Get Rating) dropped 1.6% during trading on Friday . The company traded as low as $4.91 and last traded at $4.92. Approximately 113,958 shares were traded during mid-day trading, an increase of 173% from the average daily volume of 41,754 shares. The stock had previously closed at $5.00.
Analysts Set New Price Targets
PRTG has been the subject of a number of recent analyst reports. HC Wainwright lowered their target price on shares of Portage Biotech from $22.00 to $21.00 and set a “buy” rating for the company in a research note on Thursday, December 1st. Cantor Fitzgerald reduced their price target on shares of Portage Biotech from $26.00 to $18.00 in a research report on Wednesday, November 30th. Finally, Oppenheimer reduced their price target on shares of Portage Biotech from $26.00 to $18.00 and set an “outperform” rating for the company in a research report on Wednesday, November 30th.
Portage Biotech Trading Down 1.6 %
The company has a market capitalization of $83.37 million, a PE ratio of -4.92 and a beta of 1.34. The business’s 50-day simple moving average is $5.65 and its 200-day simple moving average is $7.05.
Hedge Funds Weigh In On Portage Biotech
Portage Biotech Company Profile
Portage Biotech Inc, together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; TT-10, an adenosine receptor type 2A (A2A) inhibitor to treat A2A expressing solid tumors; TT-4, an adenosine receptor type 2B (A2B) inhibitor to treat solid tumors; TT-53, an A2A/A2B inhibitor to treat solid tumors; TT-3, an A2B inhibitor to treat colorectal and gastrointestinal cancers; and NT230-6 that is in Phase I/II clinical trials for the treatment of tumors.
- Get a free copy of the StockNews.com research report on Portage Biotech (PRTG)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Portage Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portage Biotech and related companies with MarketBeat.com's FREE daily email newsletter.